mitazalimab   Click here for help

GtoPdb Ligand ID: 13692

Synonyms: ADC-1013 | ADC1013 | JNJ-64457107 | JNJ64457107
Compound class: Antibody
Comment: Mitazalimab (formerly JNJ-64457107, or ADC-1013) is an anti-CD40 monoclonal antibody. It binds CD40 on dendritic cells (DC) as a mechanism to activate T cell-dependent anti-tumour immunity [2]. Intratumoural administration of mitazalimab induces immunostimulant activity and initiates Fc-effector functions against tumour cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Mitazalimab is being investigated in clinical trials to establish safety and afficacy as an anti-tumour immunotherapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02829099 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Phase 1 Interventional Janssen Research & Development, LLC
NCT02379741 ADC-1013 First-in-Human Study Phase 1 Interventional Alligator Bioscience AB 1
NCT04888312 Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients Phase 1/Phase 2 Interventional Alligator Bioscience AB 3